Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Non-Current Assets (2016 - 2022)

Historic Other Non-Current Assets for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Q4 2022 value amounting to $9000.0.

  • Catalyst Pharmaceuticals' Other Non-Current Assets changed 0.0% to $9000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $9000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $9000.0 for FY2022, which is 0.0% changed from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $9000.0 for Q4 2022, which was down 0.0% from $9000.0 recorded in Q3 2022.
  • In the past 5 years, Catalyst Pharmaceuticals' Other Non-Current Assets registered a high of $9000.0 during Q4 2020, and its lowest value of $8888.0 during Q1 2018.
  • Its 5-year average for Other Non-Current Assets is $8938.4, with a median of $8888.0 in 2018.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Other Non-Current Assets changed by 0.0% in 2018, and later skyrocketed by 126.01% in 2020.
  • Catalyst Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $8888.0 in 2018, then changed by 0.0% to $8888.0 in 2019, then increased by 1.26% to $9000.0 in 2020, then changed by 0.0% to $9000.0 in 2021, then changed by 0.0% to $9000.0 in 2022.
  • Its Other Non-Current Assets was $9000.0 in Q4 2022, compared to $9000.0 in Q3 2022 and $9000.0 in Q2 2022.